Summit Therapeutics to Present at Upcoming Conferences

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Summit Therapeutics to Present at Upcoming Conferences

Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will present at two upcoming conferences.

Details of the conference presentations:

• Superbugs & Superdrugs 2019: The Development of Precision Antibiotics: Agents Designed to Meet the Demands of Stewardship, on 18 March 2019 at 1:40pm GMT in London
• Oppenheimer 29th Annual Healthcare Conference: corporate presentation on 20 March 2019 at 2:10pm EDT in New York City

A live webcast of the Oppenheimer presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit
Glyn Edwards / Richard Pye (UK office)	Tel:	44 (0)1235 443 951
Michelle Avery (US office)		[phone]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:	[phone]
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)	Tel:	[phone]
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker)	Tel:	[phone]
Phil Walker / Dominic Wilson
MSL Group (US)	Tel:	[phone]
Jon Siegal		[e-mail]
Consilium Strategic Communications (UK)	Tel:	[phone]
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /		[e-mail]
Lindsey Neville

-END-